Clinical trial · Interventional
Target-specific immunoPET Imaging of Breast Cancer
Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer
NCT06715826CI-TRIAL-00101684recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Breast Cancer Metastatic | — | UNRESOLVED | — |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]F-RESCA-RB14 | Drug | — | UNRESOLVED |
| [18F]F-RESCA-RT4 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Trop2/HER2-targeted immunoPET imaging
- description
- Enrolled patients will undergo a Trop2/HER2-targeted immunoPET/CT scanning.
- interventionNames
- Drug: [18F]F-RESCA-RT4
- Drug: [18F]F-RESCA-RB14
Primary outcomes (6)
- measure
- Biodistribution of [18F]F-RESCA-RT4/ [18F]F-RESCA-RB14
- timeFrame
- 1 day from injection of the tracer
- description
- Measurement of the overall biodistribution of above probes in normal tissues and organs.
- measure
- Standardized uptake value (SUV)
- timeFrame
- 1 day from injection of the tracer
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18-75 years old and of female gender； 2. Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging; 3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. Exclusion Criteria: 1. Pregnancy； 2. Severe hepatic and renal insufficiency; 3. History of serious surgery in the last month; 4. Allergic to antibody or single-domain antibody radiopharmaceuticals.
References
Publications (0)
Data not yet available
No reference posted for this study.